2-Deoxy-D-glucose - G.ST Antivirals
Alternative Names: 2-Deoxyglucose - G.ST Antivirals; 2-DG - G.ST AntiviralsLatest Information Update: 28 Apr 2025
At a glance
- Originator University of Vienna
- Developer G.ST Antivirals
- Class Antiepileptic drugs; Antivirals; Deoxy sugars; Small molecules
- Mechanism of Action Glycolysis inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rhinovirus infections
- No development reported Nose disorders
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Nose-disorders(Prevention) in Austria (Intranasal, Spray)
- 02 Apr 2024 Phase-II clinical trials in Rhinovirus infections in Netherlands (Intranasal)
- 25 Jan 2024 Adverse events data from a phase I trial in Nose disorders released by G.ST Antivirals